Tango Therapeutics director files Form 3

Tango Therapeutics, Inc. director Robert Azelby has filed a Form 3, which is an initial statement of beneficial ownership as a company insider.

Rhea-AI Filing Summary

Tango Therapeutics, Inc. director Robert Azelby has filed a Form 3, which is an initial statement of beneficial ownership as a company insider. The filing lists him as a director but does not report any stock transactions or current holdings in this excerpt.

Key Figures

Buy transactions: 0 shares Sell transactions: 0 shares Net buy/sell direction: neutral +1 more

4 metrics

Buy transactions 0 shares Form 3 transaction summary

Sell transactions 0 shares Form 3 transaction summary

Net buy/sell direction neutral Form 3 transactionSummary netBuySellDirection

Holding entries 0 Form 3 transactionSummary holdingEntries

Key Terms

Form 3, beneficial ownership, reporting person

3 terms

Form 3 regulatory

"has filed a Form 3, which is an initial statement of beneficial ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership regulatory

"Form 3, which is an initial statement of beneficial ownership as a company insider"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

reporting person regulatory

"The filing lists him as a reporting person in the role of director"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Tango Therapeutics (TNGX) Form 3 for Robert Azelby show?

The Form 3 identifies Robert Azelby as a director of Tango Therapeutics and serves as his initial beneficial ownership report. In this excerpt, no stock transactions or existing share holdings are listed for him.

Does the TNGX Form 3 for Robert Azelby report any stock purchases or sales?

No, the summary data shows zero buy, sell, acquire, dispose, or exercise transactions. All transaction-related counts and share amounts, including net buy or sell activity, are reported as zero in this filing excerpt.

What is the purpose of a Form 3 for Tango Therapeutics insiders?

Form 3 is used to disclose an insider’s initial beneficial ownership when they become a director, officer, or large shareholder. It establishes a baseline from which future transactions will be reported on Forms 4 or 5.

Are there any derivative securities reported for Robert Azelby in this TNGX Form 3?

No, the derivative summary is empty and derivativeTransactionCount is zero. This indicates no options, warrants, or other derivative positions are reported for Robert Azelby in this particular Form 3 excerpt.

Does the Tango Therapeutics Form 3 show any holdings after the reporting date?

The transaction summary shows holdingEntries as zero, and there are no listed positions. This means the excerpt does not provide any post-reporting share balance or derivative holdings for the reporting person.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 06:04 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Azelby Robert

(Last) (First) (Middle)

C/O TANGO THERAPEUTICS, INC.

201 BROOKLINE AVE., SUITE 901

(Street)

BOSTON MASSACHUSETTS 02215

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/19/2026

3. Issuer Name and Ticker or Trading Symbol
Tango Therapeutics, Inc. [ TNGX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24: Power of Attorney

No securities are beneficially owned.

	/s/ Julie Fogarty, as attorney-in-fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)